Analystreport

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.

Dicerna Pharmaceuticals, Inc.  (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com